Lomitapide and Everolimus: Interaction Details

Brand names
Lomitapide
Juxtapid
Everolimus
Afinitor DisperzAfinitorZortress +2 more
Dr. Brian Staiger, PharmD, BCPS

Medically reviewed by ⁠

Also reviewed by the HelloPharmacist Editorial Team Updated AI-assisted Details about this page
Share

Share this interaction

Everolimus

Brand names
  • Afinitor Disperz
  • Afinitor
  • Zortress
  • Torpenz
  • Yulithira

What Happens When You Take Lomitapide With Everolimus

What can happen when they are taken together (rated Major)

Increased lomitapide exposure and an increased exposure

Interaction Deep Dive

A note from Dr. Brian Staiger If you’re a patient, this deep dive may be too technical, or bore you (or both). Read the plain-language explanation →

When lomitapide is taken together with weak that are also P-gp substrates, exposure to both lomitapide and the P-gp substrates may rise. A lower dose of the P-gp substrate should be considered during concurrent lomitapide therapy.

With a weak CYP3A4 , the recommended maximum lomitapide dosage is 10 mg for ages 2 to 10 years, 20 mg for ages 11 to 17 years, and 30 mg for those 18 years and older. The schedules in the presence of a weak CYP3A4 inhibitor are as follows.

Ages 2 to 10 years: 2 mg (weeks 0 to 8), 5 mg (weeks 9 to 12), 10 mg (weeks 13 to 16), then 20 mg from week 17 onward, and higher doses are not recommended. Ages 11 to 15 years: 2 mg (weeks 0 to 4), 5 mg (weeks 5 to 8), 10 mg (weeks 9 to 12), 20 mg (weeks 13 to 16), then 40 mg from week 17 onward, and the 60 mg dose is not recommended.

Ages 16 to 17 years: 2 mg (weeks 0 to 2), 5 mg (weeks 3 to 6), 10 mg (weeks 7 to 10), 20 mg (weeks 11 to 14), then 40 mg from week 15 onward, and the 60 mg dose is not recommended. Ages 18 years and older: the same pattern as for ages 16 to 17 years, except that a 60 mg dose is permitted after week 15.

If a weak CYP3A4 inhibitor is started in a patient already on a stable lomitapide dosage, the lomitapide dose should be cut in half. Subsequent careful titration, guided by LDL-C response and safety/tolerability, may be considered up to half of the maximum recommended dosage. The exception is with oral contraceptives alone, where the maximum recommended lomitapide dose is about two thirds of the maximum recommended dose.1

The Lomitapide and Everolimus Interaction, Explained

Lomitapide (a cholesterol medicine) and everolimus (used for certain cancers, tuberous sclerosis complex, and to prevent transplant rejection) can raise each other's levels in the body. Everolimus may slow the breakdown of lomitapide, and lomitapide may reduce how well the body clears everolimus. Higher levels can mean more side effects, such as stomach upset and liver strain from lomitapide, or more mouth sores, infections, or swelling from everolimus.

This concern is based mostly on how the drugs work, not on large studies. Your care team can manage it by adjusting doses and checking on you more closely. Please keep taking both as prescribed and talk with your pharmacist or doctor about it.

Mechanism: Everolimus is a and substrate, and is considered a weak CYP3A4 in this context. It may reduce CYP3A4-mediated of lomitapide, while lomitapide inhibits P-gp efflux and may raise everolimus exposure. Both effects increase exposure to the affected drug.

  • Severity/evidence: major; theoretical; onset unspecified.
  • Lomitapide: with a weak CYP3A4 inhibitor, cap the dose at 30 mg/day in adults (10 mg ages 2 to 10, 20 mg ages 11 to 17). If the inhibitor is started in a patient on a stable dose, reduce the lomitapide dose by half, then titrate cautiously based on LDL-C response and tolerability.
  • Everolimus: consider dose reduction as a P-gp substrate.
  • Monitor: LDL-C, enzymes, tolerability, and everolimus-related adverse effects (consider trough levels where used).

See the 2 references behind this explanation ↓

From the HelloPharmacist Pharmacy Team

AI-assisted: written with AI from this pair’s record in our interaction database, and reviewed by the HelloPharmacist pharmacy team. Written .

How we build these pages · How we use AI · Our editorial policy

Why Lomitapide and Everolimus Interact

The likely mechanism

of -mediated of lomitapide; inhibition of -mediated efflux transport by lomitapide

How Drug Interactions Work Six short figures, about a minute: how one drug can raise or lower another’s level, or add to or cancel its effect. See how it works 

How to Manage the Lomitapide and Everolimus Interaction

Your care team can manage this combination by tailoring doses and monitoring you more closely.

  • If you are already on a stable lomitapide dose and everolimus is added, your prescriber will typically lower the lomitapide dose by half, then may carefully adjust it based on your LDL cholesterol and how you tolerate it.
  • There are also maximum lomitapide doses when it is used with this kind of drug, and these vary by age.
  • Your everolimus dose may also need to be adjusted and individualized by your care team.

Keep taking both medicines as prescribed. Do not change any dose on your own. Tell your pharmacist or doctor about any new stomach problems, unusual tiredness, or other new symptoms.

Management is individual — confirm any change with your pharmacist or prescriber.

Questions for Your Pharmacist

  • Does my dose of Lomitapide or Everolimus need adjusting while I take them together?
  • What symptoms should prompt me to call you or my prescriber right away?
  • Does the timing of my doses matter for this combination?
  • Is there another option that avoids this interaction?

Literature Reports

1 report from the published literature. Each one is headed by the title of the published study it comes from.

What these reports are. Short summaries of published evidence on this combination: clinical studies, case reports and, at times, the FDA prescribing information for one of the drugs. They support this interaction, but it does not rest on them alone. It can also rest on prescribing information not summarized here, or on what is expected from how these two drugs, and others in their drug classes, are known to work.

  1. Report 1 · Study title

    Prescribing information: JUXTAPID oral capsules, lomitapide oral capsules

    When atorvastatin 80 mg daily, a weak , was coadministered with a single 20-mg dose of lomitapide, the of lomitapide rose 2-fold and its rose 2.1-fold relative to lomitapide given alone.2

Lomitapide and Everolimus: Common Questions

How serious is the Lomitapide and Everolimus interaction?

It is rated major. Potentially serious — often needs a change or close monitoring.

How is the Lomitapide and Everolimus interaction managed?

Your care team can manage this combination by tailoring doses and monitoring you more closely. If you are already on a stable lomitapide dose and everolimus is added, your prescriber will typically lower the lomitapide dose by half, then may carefully adjust it based on your LDL cholesterol and how you tolerate it. There are also maximum lomitapide doses when it is used with this kind of drug, and… Management is individual — always follow your own care team's guidance.

Who is at higher risk from the Lomitapide and Everolimus interaction?

The interaction record names this group as more likely to be affected:

  • People taking higher doses

If this describes you, tell your pharmacist or prescriber.

How quickly could this interaction happen?

The documented onset is "unspecified". The timing of this interaction is not well characterized.

How strong is the evidence for this interaction?

The evidence is graded "theoretical". Expected from how the drugs work, or from studies of similar drugs; this exact pair has little direct study.

Ask About the Lomitapide and Everolimus Interaction

Ask in your own words about taking Lomitapide and Everolimus together. The answer comes from this page’s interaction record and both drugs’ own information.

This box answers questions about this one combination only. For anything else about either drug, open its drug information page or ask a pharmacist.

Try:

AI answers from this page’s record and both drugs’ information, never the open internet. AI can make mistakes, so always check with your doctor or pharmacist.

References (2)

  1. Product Information: JUXTAPID® oral capsules, lomitapide oral capsules. Chiesi USA, Inc. (per Manufacturer), Cary, NC, 2026. DailyMed
  2. Product Information: JUXTAPID(R) oral capsules, lomitapide oral capsules. Aegerion Pharmaceuticals, Inc. (per FDA), Cambridge, MA, 2016. DailyMed
Was this write-up helpful?

Other Serious Interactions of Lomitapide and Everolimus

Also serious with Lomitapide

Also serious with Everolimus

These Medications Also Interact With Supplements

Prescription drugs aren't the whole picture — herbal and dietary supplements can interact with them too. From the evidence-graded Natural Medicines database:

With Lomitapide

With Everolimus

Check everything you take with our drug–supplement interaction checker.

Still Have Questions About This Combination?

Every question gets a real answer from a licensed pharmacist — free, and usually within a day.

About This Library

Built in-house, documented one interaction at a time. Our interaction database is not a complete list of every known interaction: a combination that isn't listed here hasn't been documented by us yet, which never means it's safe. Checking everything you take at once? Ask your pharmacist to review your full medication list. How we build and review it →

What Each Rating Means

Severity Levels

  • Contraindicated These should generally not be used together.
  • Major Potentially serious — often needs a change or close monitoring. This interaction.
  • Moderate Can be significant — usually manageable with monitoring.
  • Minor Usually limited clinical impact.

Evidence Grades

  • EstablishedWell documented — supported by controlled studies or strong clinical data.
  • ProbableGood supporting evidence, though not definitively proven.
  • SuspectedSome evidence suggests this interaction, but it is not well established.
  • PossibleLimited or conflicting evidence; the interaction may occur.
  • TheoreticalExpected from how the drugs work, or from studies of similar drugs; this exact pair has little direct study. This interaction.

How Soon It Shows

  • RapidEffects can appear quickly, often within about 24 hours of combining the drugs.
  • DelayedEffects tend to build up gradually over days to weeks.
  • UnspecifiedThe timing of this interaction is not well characterized. This interaction.

Ratings come from the documented interaction literature and are reviewed by a pharmacist. They describe the documented risk of the combination, not what will necessarily happen to you — your dose, timing, and health picture all matter.

Back to the answer
This information is for education, not a substitute for professional medical advice. Do not start, stop, or change any medication without talking to your pharmacist or prescriber.